227 related articles for article (PubMed ID: 15827130)
1. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
[TBL] [Abstract][Full Text] [Related]
2. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Schmitt M; Schmitt A; Rojewski MT; Chen J; Giannopoulos K; Fei F; Yu Y; Götz M; Heyduk M; Ritter G; Speiser DE; Gnjatic S; Guillaume P; Ringhoffer M; Schlenk RF; Liebisch P; Bunjes D; Shiku H; Dohner H; Greiner J
Blood; 2008 Feb; 111(3):1357-65. PubMed ID: 17978170
[TBL] [Abstract][Full Text] [Related]
3. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
5. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
Chen J; Schmitt A; Bunjes D; Chen B; Schmitt M
Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013
[TBL] [Abstract][Full Text] [Related]
6. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
Chen J; Schmitt A; Chen B; Rojewski M; Ringhoffer M; von Harsdorf S; Greiner J; Guillaume P; Döhner H; Bunjes D; Schmitt M
Cancer Immunol Immunother; 2007 Jun; 56(6):849-61. PubMed ID: 17009043
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
[TBL] [Abstract][Full Text] [Related]
8. Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.
Tabarkiewicz J; Giannopoulos K
Transplant Proc; 2010 Oct; 42(8):3293-6. PubMed ID: 20970674
[TBL] [Abstract][Full Text] [Related]
9. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
10. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses.
Schmitt A; Barth TF; Beyer E; Borchert F; Rojewski M; Chen J; Guillaume P; Gronau S; Greiner J; Möller P; Riechelmann H; Schmitt M
Int J Oncol; 2009 Mar; 34(3):629-39. PubMed ID: 19212667
[TBL] [Abstract][Full Text] [Related]
11. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
[TBL] [Abstract][Full Text] [Related]
12. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
Giannopoulos K; Li L; Bojarska-Junak A; Rolinski J; Dmoszynska A; Hus I; Greiner J; Renner C; Döhner H; Schmitt M
Int J Oncol; 2006 Jul; 29(1):95-103. PubMed ID: 16773189
[TBL] [Abstract][Full Text] [Related]
13. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
14. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.
Greiner J; Schmitt A; Giannopoulos K; Rojewski MT; Götz M; Funk I; Ringhoffer M; Bunjes D; Hofmann S; Ritter G; Döhner H; Schmitt M
Haematologica; 2010 Jul; 95(7):1191-7. PubMed ID: 20081055
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867
[TBL] [Abstract][Full Text] [Related]
16. Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Meier C; Schmitt A; Spitschak A; Hilgendorf I; Rohde S; Hirt C; Freund M; Pützer BM; Schmitt M
Clin Dev Immunol; 2012; 2012():146463. PubMed ID: 22719778
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
18. Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.
Belle S; Han F; Condomines M; Christensen O; Witzens-Harig M; Kasper B; Kleist C; Terness P; Moos M; Cremer F; Hose D; Ho AD; Goldschmidt H; Klein B; Hundemer M
Eur J Haematol; 2008 Jul; 81(1):26-35. PubMed ID: 18363871
[TBL] [Abstract][Full Text] [Related]
19. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.
Bai J; Wang J; Yang Y; Wang F; He A; Zhang W
J Immunother; 2021 May; 44(4):141-150. PubMed ID: 33596023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
